Ensign Peak Advisors
XENE icon

Ensign Peak Advisors’s Xenon Pharmaceuticals XENE Stock Holding History

Ensign Peak Advisors’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$326K Buy
5,394
+200
+4% +$11.1K ﹤0.01% 1140
2026
Q1 		$302K Hold
5,194
– – ﹤0.01% 1123
2025
Q4 		$233K Sell
5,194
-10,050
-66% -$422K ﹤0.01% 1240
2025
Q3 		$612K Sell
15,244
-10,850
-42% -$382K ﹤0.01% 1299
2025
Q2 		$817K Hold
26,094
– – ﹤0.01% 1365
2025
Q1 		$875K Hold
26,094
– – ﹤0.01% 1325
2024
Q4 		$1.02M Sell
26,094
-136,970
-84% -$5.66M ﹤0.01% 1306
2024
Q3 		$6.42M Hold
163,064
– – 0.01% 557
2024
Q2 		$6.36M Hold
163,064
– – 0.01% 564
2024
Q1 		$7.02M Sell
163,064
-1,316
-0.8% -$60.5K 0.01% 540
2023
Q4 		$7.57M Hold
164,380
– – 0.02% 514
2023
Q3 		$5.62M Hold
164,380
– – 0.01% 535
2023
Q2 		$6.33M Hold
164,380
– – 0.01% 526
2023
Q1 		$5.88M Hold
164,380
– – 0.01% 524
2022
Q4 		$6.48M Buy
164,380
+50,900
+45% +$1.85M 0.01% 499
2022
Q3 		$4.1M Buy
113,480
+57,189
+102% +$2.06M 0.01% 571
2022
Q2 		$1.71M Buy
56,291
+47,771
+561% +$1.44M ﹤0.01% 863
2022
Q1 		$260K Sell
8,520
-28,595
-77% -$856K ﹤0.01% 1801
2021
Q4 		$1.16M Buy
37,115
+5,600
+18% +$167K ﹤0.01% 1199
2021
Q3 		$482K Buy
+31,515
New +$548K ﹤0.01% 1631

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Ensign Peak Advisors's XENE Position: Q2 2026 in Review

Ensign Peak Advisors increased its Xenon Pharmaceuticals (XENE) stake by 3.9% in Q2 2026, buying an estimated $11.1K and bringing the position to 5,394 shares worth $326K. The position accounts for ﹤0.01% of the portfolio, ranked #1140.

Ensign Peak Advisors first reported a position in XENE in Q3 2021 and has held it in 20 quarters since. The position peaked at $7.57M in Q4 2023. 316 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Ensign Peak Advisors held 5,394 shares of Xenon Pharmaceuticals worth $326K as of Q2 2026.
  • Ensign Peak Advisors bought 200 Xenon Pharmaceuticals shares in Q2 2026, an estimated $11.1K.
  • Xenon Pharmaceuticals made up ﹤0.01% of Ensign Peak Advisors's portfolio in Q2 2026, its #1140 holding.
  • Ensign Peak Advisors first reported a position in Xenon Pharmaceuticals in Q3 2021 and has held it in 20 quarters since.
  • Ensign Peak Advisors's Xenon Pharmaceuticals position peaked at $7.57M in Q4 2023.
  • 316 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Ensign Peak Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.